MAD2L1 and hepatocellular carcinoma: Survival analysis showed that overexpression of MAD2L1 was associated with poor prognosis, reducing the overall survival time (P = 0.014) and disease-free survival time (P = 0.028) of HCC patients (Figures 6(e) and 6(f)).